Диссертация (1140142), страница 21
Текст из файла (страница 21)
169, № 2. ‒ P. 287293.279. Singh H., Kumaran M.S., Bains A., Parsad D. A RandomizedComparative Study of Oral Corticosteroid Minipulse and Low-Dose OralMethotrexate in the Treatment of Unstable Vitiligo // Dermatology. ‒ 2015. ‒ Vol.231, № 3. ‒ P. 286-90.280. Singhal P., Agarwal S., Dhot P.S., Sayal S.K. Efficacy of platelet-richplasma in treatment of androgenic alopecia // Asian J. Transfus. Sci.
‒ 2015. ‒ Vol.9, № 2. ‒ P. 159-162.281. Sitek J.C., Loeb M., Ronnevig J.R. Narrowband UVB therapy forvitiligo: does the repigmentation last? // J. Eur. Acad. Dermatol. Venereol. ‒ 2007.‒ Vol. 21, № 7. ‒ P. 891-896.282. Smith P.A. Intra-articular Autologous Conditioned Plasma InjectionsProvide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDASanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial // Am. J.Sports Med.
‒ 2016. ‒ Vol. 44, № 4. ‒ P. 884-891.283. Song M.S., Hann S.K., Ahn P.S. et al. Clinical study of vitiligo:comparative study of type A and type B vitiligo // Ann. Dermatol. - 1994. - Vol. 83(6). - P. 22-30.284. Speeckaert R., Speeckaert M.M., van Geel N. Why treatments do(n't)work in vitiligo: An autoinflammatory perspective // Autoimmun. Rev. ‒ 2015. ‒Vol.
14, № 4. ‒ P. 332-340.285. Speeckaert R., van Geel N. Vitiligo: An Update on Pathophysiologyand Treatment Options // Am J Clin Dermatol. ‒ 2017. ‒ Vol. 18, № 6. ‒ P. 733-129744.286. Spritz R.A. Six decades of vitiligo genetics: genome-wide studiesprovide insights into autoimmune pathogenesis // J. Invest. Dermatol. ‒ 2012.
‒Vol. 132, № 2. ‒ P. 268-273.287. Spritz R.A., Andersen G.H. Genetics of Vitiligo // Dermatol. Clin. ‒2017. ‒ Vol. 35, № 2. ‒ P. 245-255.288. Suthar M., Gupta S., Bukhari S., Ponemone V. Treatment of chronicnon-healing ulcers using autologous platelet rich plasma: a case series // J.
Biomed.Sci. ‒ 2017. ‒ Vol. 24, № 1. ‒ P. 16.289. Takata T., Tarutani M., Sano S. A failure in endothelin-1 productionfrom vitiligo keratinocytes in response to ultraviolet B irradiation // J. Dermatol.Sci.- 2013. -Vol.71(3).- P.210-212.290. Taieb A., Alomar A., Bohm M.
et al. Guidelines for the managementof vitiligo: the European Dermatology Forum consensus // Br. J. Dermatol. ‒ 2013.‒ Vol. 168, № 1. ‒ P. 5-19.291. Taieb A., Picardo M. Clinical practice. Vitiligo // N. Engl. J. Med. ‒2009. ‒ Vol. 360, № 2. ‒ P. 160-169.292. Taieb A., Picardo M., Members V. The definition and assessment ofvitiligo: a consensus report of the Vitiligo European Task Force // Pigment CellRes. ‒ 2007. ‒ Vol. 20, № 1.
‒ P. 27-35.293. Tembhre M.K., Sharma V.K., Sharma A. et al. T helper and regulatoryT cell cytokine profile in active, stable and narrow band ultraviolet B treatedgeneralized vitiligo // Clin. Chim. Acta. ‒ 2013. ‒ Vol. 424. ‒ P. 27-32.294. Terazawa S., Nakajima H., Fukasawa K. et al. Withaferin A abolishesthe stem cell factor-stimulated pigmentation of human epidermal equivalents byinterrupting the auto-phosphorylation of c-KIT in human melanocytes // Arch.Dermatol. Res. - 2015.
- Vol.307 (1).- P.73-88.295. Thannickal V.J., Day R.M., Klinz S.G. et al. Ras-dependent and independent regulation of reactive oxygen species by mitogenic growth factors andTGF-beta1 // FASEB J. - 2000. -Vol.14 (12). - P.1741-1748.130296. Toosi S., Orlow S.J., Manga P. Vitiligo-inducing phenols activate theunfolded protein response in melanocytes resulting in upregulation of IL6 and IL8// J. Invest. Dermatol. ‒ 2012. ‒ Vol. 132, № 11. ‒ P. 2601-2609.297.
Vallerand I.A., Lewinson R.T., Parsons L.M. et al. Vitiligo and majordepressive disorder: A bidirectional population-based cohort study // J Am AcadDermatol. - 2019. - Vol.80(5). - P.1371-1379.298. van Buul G.M., Koevoet W.L., Kops N. et al.
Platelet-rich plasmareleasate inhibits inflammatory processes in osteoarthritic chondrocytes // Am. J.Sports Med. ‒ 2011. ‒ Vol. 39, № 11. ‒ P. 2362-2370.299. van den Boorn J.G., Jakobs C., Hagen C. et al. InflammasomeDependent Induction of Adaptive NK Cell Memory // Immunity. ‒ 2016. ‒ Vol.44, № 6. ‒ P. 1406-1421.300. van den Boorn J.G., Konijnenberg D., Dellemijn T.A. et al.Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligopatients // J. Invest. Dermatol.
‒ 2009. ‒ Vol. 129, № 9. ‒ P. 2220-2232.301. Van Den Bossche K., Naeyaert J.M., Lambert J. The quest for themechanism of melanin transfer // Traffic. - 2006. - Vol.7(7). - P.769-778.302. van Geel N., Speeckaert M., Brochez L. et al. Clinical profile ofgeneralized vitiligo patients with associated autoimmune/autoinflammatorydiseases // J. Eur. Acad. Dermatol. Venereol. ‒ 2014.
‒ Vol. 28, № 6. ‒ P. 741-746.303. van Geel N., Speeckaert R., Mollet I. et al. In vivo vitiligo inductionand therapy model: double-blind, randomized clinical trial // Pigment CellMelanoma Res. ‒ 2012. ‒ Vol. 25, № 1. ‒ P. 57-65.304. Vandercappellen J., Van Damme J., Struyf S. The role of the CXCchemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) ininflammation, angiogenesis and cancer // Cytokine Growth Factor Rev.
‒ 2011. ‒Vol. 22, № 1. ‒ P. 1-18.305. Vanscheidt W., Hunziker T. Repigmentation by outer-root-sheathderived melanocytes: proof of concept in vitiligo and leucoderma // Dermatology.‒ 2009. ‒ Vol. 218, № 4. ‒ P. 342-343.131306. Vasistha L.K., Singh G. Vitiligo and intralesional steroids // Indian JMed Res. ‒ 1979. ‒ Vol. 69. ‒ P. 308-311.307. Vrijman C., Kroon M.W., Limpens J. et al. The prevalence of thyroiddisease in patients with vitiligo: a systematic review // Br. J. Dermatol. ‒ 2012.
‒Vol. 167, № 6. ‒ P. 1224-1235.308. Wan P., Hu Y., He L. Regulation of melanocyte pivotal transcriptionfactor MITF by some other transcription factors // Mol Cell Biochem. - 2011. Vol.354 (1-2). -P.241-246.309. Wang E., Koo J., Levy E. Intralesional corticosteroid injections forvitiligo: a new therapeutic option // J.
Am. Acad. Dermatol. ‒ 2014. ‒ Vol. 71, №2. ‒ P. 391-393.310. Wang S., Zhou M., Lin F. et al. Interferon-g induces senescence innormal human melanocytes // PLoS One. - 2014. - Vol.9(3):e93232311. Wang X.X., Wang Q.Q., Wu J.Q. et al. Increased expression ofCXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinicalmarker for vitiligo // Br. J. Dermatol.
‒ 2016. ‒ Vol. 174, № 6. ‒ P. 1318-1326.312. Wang Z., Zhang H., Xu X. et al. bFGF inhibits ER stress induced byischemic oxidative injury via activation of the PI3K/Akt and ERK1/2 pathways //Toxicol Lett. - 2012. -Vol.212(2).- P.137-146.313. Webb K.C., Tung R., Winterfield L.S. et al. Tumour necrosis factoralpha inhibition can stabilize disease in progressive vitiligo // Br.
J. Dermatol. ‒2015. ‒ Vol. 173, № 3. ‒ P. 641-650.314. Weber S.C., Kauffman J.I., Parise C. et al. Platelet-rich fibrin matrixin the management of arthroscopic repair of the rotator cuff: a prospective,randomized, double-blinded study // Am. J. Sports Med. ‒ 2013. ‒ Vol. 41, № 2. ‒P. 263-270.315.
Weibrich G., Kleis W.K., Hafner G. et al. Comparison of platelet,leukocyte, and growth factor levels in point-of-care platelet-enriched plasma,prepared using a modified Curasan kit, with preparations received from a localblood bank // Clin. Oral Implants Res. ‒ 2003. ‒ Vol. 14, № 3. ‒ P. 357-362.132316. Westerhof W., Nieweboer-Krobotova L. Treatment of vitiligo withUV-B radiation vs topical psoralen plus UV-A // Arch.
Dermatol. - 1997. Vol.133. - P.1525-1528.317. Westerhof W., d’Ischia M. Vitiligo puzzle: the pieces fall in place //Pigment. Cell Res. - 2007. - Vol.20(5). - P.345-359.318. Whitton M., Pinart M., Batchelor J.M. et al. Evidence-basedmanagement of vitiligo: summary of a Cochrane systematic review // Br. J.Dermatol. ‒ 2016. ‒ Vol. 174, № 5. ‒ P. 962-969.319. Wolkerstorfer A. The long road to valid outcomes in vitiligo // Br JDermatol. - 2019. - Vol.180(3).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
